PatientsVille.com Logo

Radical and Avodart

PatientsVille

Radical Symptoms and Causes

The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American.

Symptoms of prostate cancer may include

  • Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling
  • Low back pain
  • Pain with ejaculation

To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy.

Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments.

NIH: National Cancer Institute

Check out the latest treatments for radical

radical treatment research studies

Avodart clinical trials, surveys and public health registries


Find Drug Side Effect reports



Avodart Side Effects

Erectile Dysfunction (148)
Breast Enlargement (140)
Breast Tenderness (132)
Libido Decreased (111)
Pollakiuria (107)
Gynaecomastia (106)
Dizziness (99)
Rash (94)
Semen Volume Decreased (82)
Breast Pain (81)
Prostatic Specific Antigen Increased (75)
Dysuria (74)
Product Quality Issue (73)
Fatigue (69)
Pruritus (68)
Breast Swelling (63)
Nipple Pain (58)
Asthenia (58)
Urine Flow Decreased (57)
Nocturia (54)
Prostate Cancer (54)
Nausea (52)
Arthralgia (48)
Pain (47)
Headache (44)
Alopecia (42)
Insomnia (42)
Dyspnoea (39)
Constipation (38)
Pain In Extremity (36)
Oedema Peripheral (36)
Myalgia (36)
Breast Mass (35)
Ill-defined Disorder (34)
Diarrhoea (34)
Abdominal Pain Upper (33)
Chest Pain (32)
Therapeutic Response Unexpected (31)
Urinary Retention (30)
Ejaculation Disorder (30)
Micturition Urgency (29)
Back Pain (28)
Malaise (28)
Accidental Exposure (28)
Ejaculation Failure (27)
Blood Pressure Increased (27)
Urticaria (27)
Sexual Dysfunction (26)
Erythema (25)
Loss Of Libido (25)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After taking Avodart for three days, I experienced severe chest tightening. I immediately stopped taking the drug. It took three weeks for the chest tightening to disappear. I waited five weeks and took one dose. The following day, mild chest tighten

Any reports of increase back pain while taking Avodart. Doctor also wants me to also take Flomax while takinng Avodart

Avodart is doing what it is supposed to do - shrink my prostate. Side effects include a good deal of fatigue during day; also no semon. A side benefit is that I sleep better than I have in years!

Did you stop taking avodart and if so, how long did the stomach pain persist?

DOES AVODART CAUSE STOMACH DISCOMFORT? IF SO WHAT CAN I DO? I feel so uncomfortable.

Frequent urge to urinate with abdominal cramping, coupled with extreme gas and digestive pain, bloating of abdomen, rectaldiscomfort... this after 3rd week of Avodart use... particularly severe after lying down for any extended time... Fati

Has anyone been successfully treated with Avodart? Please email me: mark566@hotmail.com. Mark

Has anyone experienced severe anxiety that does not respond to the normal therapy while on avodart for over one year, and blurred vision as well? i stopped the med 6 weeks ago and the anxiety is just starting to get a little better day by day but the

Have taken avodart for 1year and have lost 40 lbs.

Husband has been taking avodart for 3 years. Developed a tightness in lungs, dry, non-productive cough, lungs feel a burning sensation. Thorough heart echo tests done, stress test. chest x-ray, mri, blood work, pulmonary function tests all passed.

Feb 2009 hospitalized for pericardal effusion then suffered with reaccuring pericarditis for a year march 2101 sent to mayo clinic in minnasota for a radical pericardectomy

Radical Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State
Condition: Urologic Diseases
Interventions: Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;   Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Outcome Measures: Pharmacokinetic (PK) profile of second generation dutasteride when co-administered with tamsulosin HCL relative to the commercial combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   Composite of PK parameters for tamsulosin HCl when it is co-administered with second generation dutasteride relative to the currently available commercial dutasteride 0.5 mg + tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   PK profile of dutasteride;   PK profile of tamsulosin HCl;   Clinically significant changes in Vital signs measurements to assess safety and tolerability;   Incidence of adverse events (AEs);   Clinical laboratory parameter assessment as a measure of safety and tolerability
2 Recruiting Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State
Condition: Urologic Diseases
Interventions: Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;   Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Outcome Measures: Pharmacokinetic profile for second generation dutasteride when co-administered with tamsulosin HCL relative to the currently available commercial combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   Composite of PK parameters for tamsulosin HCL when it is co-adminstered with second generation dutasteride relative to the currently available commercial dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   PK profile of dutasteride;   PK profile of tamsulosin HCL;   Clinically significant changes in Vital signs measurements to assess safety and tolerability;   Incidence of adverse events (AEs);   Clinical laboratory parameter assessment as a measure of safety and tolerability
3 Recruiting Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
Conditions: Prostate Cancer;   Erectile Dysfunction;   Urinary Toxicity
Interventions: Drug: LHRH agonist and Bicalutamide;   Drug: Bicalutamide, Dutasteride and Tamoxifen
Outcome Measures: Total prostate volume;   EPIC questionnaire urinary function and bother scores;   EPIC questionnaire sexual function and bother scores;   EPIC questionnaire bowel function and bother scores;   EPIC questionnaire hormonal function and bother scores;   IPSS scores;   Acute urinary retention rates;   SF-12 Quality of life questionnaire results;   Rate of gynecomastia and breast tenderness;   Serum testosterone;   Anemia;   Abnormal liver function tests;   Serum PSA;   Adverse events recording
4 Recruiting Dutasteride Treatment for the Reduction of Heavy Drinking in Men
Conditions: Alcoholism;   Alcohol Abuse;   Alcohol Dependence
Interventions: Drug: Dutasteride;   Drug: sugar pill
Outcome Measures: Drinks per week and heavy drinking days per week;   Moderation of treatment effect by genetic variation in AKR1C3;   Moderation of treatment effect by genetic variation in SRD5A1 and SRD5A2;   Severity of alcohol-related problems
5 Not yet recruiting Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Condition: Alopecia
Interventions: Drug: Dutasteride;   Drug: Placebo
Outcome Measures: Proportion of subjects with a change in sexual function defined as a negative change from baseline in the IIEF-EF score of >=4 units or a score of <=25 on or before Week 24;   Proportion of subjects with a negative change from baseline in the IIEF-EF score of >=4 units or a score of <=25 on or before Weeks 4 and 12 as well as the Follow-up Visit;   Change from baseline in total score of the IIEF at Weeks 4, 12, and 24 as well as the Follow-up Visit;   Change from baseline in the individual domain scores: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall sexual satisfaction, of the IIEF at Weeks 4, 12 and 24 as well as the Follow-up Visit;   Change from baseline in subject satisfaction with hair growth as assessed by the total score of the Hair Growth Satisfaction Scale (HGSS) at Weeks 12 and 24;   Change from baseline in the total score of the Dermatology Life Quality Index (DLQI) at Weeks 12 and 24;   Occurrence of adverse events related to sexual dysfunction
6 Unknown  Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia
Condition: Prostate Cancer
Interventions: Drug: dutasteride;   Procedure: prostate biopsy
Outcome Measures: rate of prostate cancer at repeated transrectal ultrasound guided biopsies in case of HPIN;   effect of 5 alfa reductase inhibitor (dutasteride) on prevention of prostate cancer development for patients with high grade intraepithelial neoplasia (HPIN).
7 Not yet recruiting ITT-5 Mechanisms of Spermatogenesis
Condition: Gonadotropin Deficiency
Interventions: Drug: Testosterone 1% Gel;   Drug: Acyline;   Drug: Dutasteride;   Drug: Ketoconazole;   Drug: HCG;   Drug: placebo dutasteride;   Drug: placebo ketoconazole
Outcome Measures: Sperm concentration;   IT steroid concentration
8 Recruiting Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Condition: Prostatic Hyperplasia
Intervention: Drug: Dutasteride/Tamsulosin
Outcome Measures: Use the number of participants with adverse events,serious adverse events and treatment-related adverse events as a measure of Safety;   Use changes in International Prostate symptom score (IPSS) and Qmax (Maximum rate of Urinary Flow (ml/sec) as a measure of Efficacy
9 Recruiting Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride 0.5mg capsules;   Drug: Dutasteride placebo capsules;   Drug: Tamsulosin 0.2mg tablets;   Drug: Disintegrating placebo tamsulosin tablet
Outcome Measures: Change From Baseline in the International Prostate Symptom Score (IPSS) at Year 2;   Percentage change from Baseline in Prostate Volume;   Proportion of subjects with IPSS improvement of >=2 points and >=3 points from baseline and, separately, >=25% improvement from Baseline;   Change from Baseline in maximum urinary flow rate (Qmax);   Proportion of subjects with Qmax improvement of >=3 milliliter per second (mL/sec) and, separately, >=30% improvement from baseline;   Time to event/ proportion of subjects with acute urinary retention (AUR) or BPH related prostatic surgery;   Time to event/proportion of subjects with AUR;   Time to event/proportion of subjects undergoing BPH related prostatic surgery
10 Unknown  Dutasteride in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: dutasteride;   Drug: gadolinium-chelate;   Other: active surveillance;   Procedure: diffusion-weighted magnetic resonance imaging;   Procedure: functional magnetic resonance imaging;   Procedure: prostate biopsy;   Procedure: ultrasound imaging
Outcome Measures: The change in volume of foci of prostate cancer (PC) as assessed by T2-weighted (T2w) MRI between baseline and 6 months;   The change in volume of PC as determined by gadolinium-enhanced (GE) MRI and diffusion-weighted (DW) MRI at 6 months;   The change in volume of PC as determined by T2w MRI, GE MRI, and DW MRI at 3 months;   The changes in MR characteristics of PC (perfusion, cell density) between baseline and 6 months;   The change in volume of PC as assessed by HistoScan transrectal ultrasound (TRUS) between baseline and 6 months;   The association between the measured PC volumes on MRI with the measured PC volumes on TRUS at baseline and 6 months;   The association between the measured changes in PC volume using MRI vs TRUS at baseline and 6 months;   The association of PC volume change with qualitative changes seen on TRUS between baseline and 6 months;   The association between MR changes in volume and characteristics with histological features as seen on 6-month biopsy (Gleason score and sum, number of cores involved, cancer core length)
11 Recruiting Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride
Condition: Benign Prostate Hyperplasia
Interventions: Drug: Tadalafil;   Drug: Dutasteride
Outcome Measures: Area Under Curve (AUC) of tadalafil;   Cmax of tadalafil;   Area Under Curve (AUC) of dutasteride;   Cmax of dutasteride
12 Recruiting Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
Conditions: Prostatic Neoplasms;   Low Grade Prostate Cancer
Interventions: Other: Dietary intervention first;   Drug: Drug (Dutasteride) intervention first
Outcome Measures: Effects of the Interventions on Lipid Metabolism From Blood and Prostatic Microenvironment;   Effect of Interventions on Gene Expression Profile;   Effects of Interventions on Hormonal Metabolism;   Determine the Clinical Utility of Urine-Based Cancer Markers in the Context of Interventions to Reduce Cancer Progression
13 Recruiting Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Bicalutamide;   Drug: Dutasteride;   Drug: Finasteride;   Radiation: Radiation
Outcome Measures: Quality of Life;   Progression Free Survival
14 Recruiting Finasteride, Dutasteride and Insulin Action
Condition: Healthy Volunteers
Interventions: Drug: Finasteride;   Drug: Dutasteride
Outcome Measures: insulin sensitivity;   adipose tissue insulin sensitivity
15 Recruiting JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Conditions: Benign Prostatic Hyperplasia;   Chronic Prostatitis
Interventions: Drug: Jalyn;   Drug: Placebo
Outcome Measures: Chronic Prostatitis Symptom Index (CPSI);   Pain subdomain;   IPSS;   GRA;   Urinary subdomain;   Quality of Life subdomain
16 Recruiting Prospective Sexual Function Study for BPH Subjects
Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride plus tamsulosin;   Drug: Placebo
Outcome Measures: Changes in total score from the full men's sexual health questionnaire (MSHQ) which has domains for erectile dysfunction, ejaculatory function and libido.;   Change in scores from the full Men's Sexual Health Questionnaire (MSHQ) from baseline at 1, 3, 6 and 9 months;   The percentage of subjects reaching the following thresholds: +10 points, +20 points,+25 points, -10 points, -20 points, -25 points, change in total MSHQ from baseline at 12 months;   Change in scores from ED, EjD and libido domains from baseline at 1, 3, 6, 9 and 12 months.;   Change in scores from baseline IPSS questionnaire scores, Quality of Life (BPH Impact Index -BII scores) and perception of treatment benefit/satisfaction with treatment (PPSM questionnaire scores) at 2 weeks an 1, 3, 6 ,9 and 12 months;   Change in MSHQ scores from baseline at 12 months in subpopulations of men with good BPH symptomatic response;   Assess the duration of events both during the treatment phase and after treatment discontinuation by following up men with sexual adverse events who withdraw from the study or men with sexual apresent at the last visit of the treatment phase
17 Unknown  The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Condition: Prostate Cancer
Intervention:
Outcome Measure: